4.4 Article

Elevated anti-Mullerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus

Journal

CLINICAL ENDOCRINOLOGY
Volume 74, Issue 1, Pages 73-78

Publisher

WILEY
DOI: 10.1111/j.1365-2265.2010.03887.x

Keywords

-

Funding

  1. Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT, Chile) [1100123]
  2. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina) [PIP-11220090100615]
  3. Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT, Argentina) [PICT-10-0521]

Ask authors/readers for more resources

Objective Elevated anti-Mullerian hormone (AMH) and adrenal androgen levels have been observed during childhood in girls at risk of developing polycystic ovarian syndrome (PCOS). The aim of this study was to evaluate ovarian function and adrenal steroid levels in prepubertal girls with type 1 diabetes mellitus (T1D). Design Cross-sectional study. Patients/Measurements We evaluated hormonal and ultrasonographic characteristics in girls with T1D (N = 73) and compared them to characteristics found in a control group of healthy girls (N = 86). Data are reported as geometric means (95% CI). Results Prepubertal girls with T1D had higher levels of AMH (29.1 pmol/l (23.2-36.3) vs 20.9 pmol/l (16.6-26.1), P = 0.038), inhibin B (arithmetic mean: 16 7 pg/ml (11.6-21.7) vs 11.7 pg/ml (10.0-13.5), P = 0.044) and dehydroepiandrosterone sulphate (DHEAS) (0.3 nmol/l (0.2-0.6) vs 0.2 nmol/l (0.1-0.3)) than controls (P = 0.045). During puberty, decreasing AMH levels were observed in girls with T1D only (P < 0.0001). Girls with T1D in Tanner stages 4-5 had lower AMH levels than their paired healthy controls (10.1 pmol/l (7.4-13.9) vs 15.7 pmol/l (11.6-21.3), respectively, P = 0.047). Conclusions Our observations indicate that prepubertal girls with T1D may exhibit similar endocrine findings to those of other girls at risk of developing PCOS. The elevated levels of AMH and inhibin B suggest that higher numbers of follicles are present in the ovary during childhood in these patients and that insulin treatment may act as a local growth factor. In addition, AMH levels differed in prepubertal and pubertal girls, suggesting that the effect of T1D on ovarian folliculogenesis changes once gonadotrophin levels rise during puberty.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Endocrinology & Metabolism

The Role of Androgen Signaling in Male Sexual Development at Puberty

Rodolfo A. Rey

Summary: Puberty is characterized by major changes in the anatomy and function of reproductive organs, with androgen playing a crucial role in this process.

ENDOCRINOLOGY (2021)

Review Developmental Biology

AMH and AMHR2 Involvement in Congenital Disorders of Sex Development

Franco G. Brunello, Rodolfo A. Rey

Summary: Anti-mullerian hormone (AMH) is crucial for male fetal genital development, with its deficiency potentially leading to abnormalities. Defects in the AMH pathway, resulting in Persistent Mullerian Duct Syndrome, cause a rare condition where patients have male external genitalia but also internal female reproductive organs.

SEXUAL DEVELOPMENT (2022)

Editorial Material Endocrinology & Metabolism

Genetics of reproductive endocrinology Preface

Rodolfo A. Rey

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Endocrinology & Metabolism

Growth, puberty and testicular function in boys born small for gestational age with a nonspecific disorder of sex development

Lloyd J. W. Tack, Saskia van der Straaten, Stefan Riedl, Alexander Springer, Paul-Martin Holterhus, Nadine C. Hornig, Zofia Kolesinska, Marek Niedziela, Federico Baronio, Antonio Balsamo, Sabine E. Hannema, Anna Nordenstrom, Sukran Poyrazoglu, Fatma F. Darendeliler, Romina Grinspon, Rodolfo Rey, Fahad Aljuraibah, Jillian Bryce, Faisal Ahmed, Rieko Tadokoro-Cuccaro, Ieuan Hughes, Guilherme Guaragna-Filho, Andrea T. Maciel-Guerra, Gil Guerra-Junior, Martine Cools

Summary: The study found that almost one out of three SGA boys experience insufficient catch-up growth by the age of 2. Additionally, SGA boys had higher LH levels during minipuberty and lower testosterone levels in stimulation tests.

CLINICAL ENDOCRINOLOGY (2022)

Review Endocrinology & Metabolism

Up-to-Date Clinical and Biochemical Workup of the Child and the Adolescent with a Suspected Disorder of Sex Development

Romina P. Grinspon, Sebastian Castro, Rodolfo A. Rey

Summary: In this review, we present a practical and updated approach to clinical and hormonal laboratory workup for newborns, children, and adolescents with suspected DSD. We emphasize the importance of tailoring the diagnostic approach based on age and presentation.

HORMONE RESEARCH IN PAEDIATRICS (2023)

Review Endocrinology & Metabolism

Disorders of Sex Development of Adrenal Origin

Gabriela P. Finkielstain, Ana Vieites, Ignacio Bergada, Rodolfo A. Rey

Summary: Disorders of Sex Development (DSD) refer to anomalies in fetal sexual differentiation resulting in discordance between chromosomal sex and gonadal or genitalia sex. DSD can be associated with adrenal disorders in both 46,XX and 46,XY individuals, with different pathogenic mechanisms. The pathophysiology, clinical presentation, and management of these disorders are reviewed, focusing on biomarkers and therapeutic development.

FRONTIERS IN ENDOCRINOLOGY (2021)

Review Endocrinology & Metabolism

Recent advancement in the treatment of boys and adolescents with hypogonadism

Rodolfo A. Rey

Summary: Clinical manifestations and treatment needs of hypogonadism in males vary according to age. Early onset hypogonadism may result in disorders of sex development, while hypogonadism established later in fetal life presents with micropenis, cryptorchidism, and/or micro-orchidism. Diagnosis of hypogonadism becomes challenging after neonatal activation of the gonadal axis diminishes. Treatment usually focuses on micropenis and/or cryptorchidism in infancy and childhood, and on lack of pubertal development and relative short stature in teenagers.

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2022)

Editorial Material Endocrinology & Metabolism

Next-Generation Sequencing as First-Line Diagnostic Test in Patients With Disorders of Sex Development?

Rodolfo A. Rey

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Pediatrics

Delayed Puberty Due to a WDR11 Truncation at Its N-Terminal Domain Leading to a Mild Form of Ciliopathy Presenting With Dissociated Central Hypogonadism: Case Report

Sebastian Castro, Franco G. Brunello, Gabriela Sanso, Paula Scaglia, Maria Esnaola Azcoiti, Agustin Izquierdo, Florencia Villegas, Ignacio Bergada, Maria Gabriela Ropelato, Marcelo A. Marti, Rodolfo A. Rey, Romina P. Grinspon

Summary: Pubertal delay in males can be caused by constitutional delay of growth and puberty or pathologic hypogonadism. Central (or hypogonadotropic) hypogonadism, resulting from a defective function of the GnRH/gonadotropin axis, is the main differential diagnosis after ruling out general illnesses and primary testicular failure. Ciliopathies arising from defects in non-motile cilia can cause developmental disorders affecting the sense organs and reproductive system.

FRONTIERS IN PEDIATRICS (2022)

Review Endocrinology & Metabolism

AMH Regulation by Steroids in the Mammalian Testis: Underlying Mechanisms and Clinical Implications

Nadia Y. Edelsztein, Clara Valeri, Maria M. Lovaisa, Helena F. Schteingart, Rodolfo A. Rey

Summary: Anti-Mullerian hormone (AMH) is a biomarker of immature Sertoli cells, which is regulated by specific transcription factors and plays a role in the regression of Mullerian ducts in males. AMH is highly expressed before puberty and then downregulated. FSH increases AMH output, while intratesticular levels of androgens and estrogens also regulate AMH secretion.

FRONTIERS IN ENDOCRINOLOGY (2022)

Article Pharmacology & Pharmacy

Considerations when treating male pubertal delay pharmacologically

Rodolfo A. Rey

Summary: This review discusses the etiologies and specific pharmacological therapies for delayed puberty in males. There is limited high-quality evidence available for the best pharmacological therapy approach, with most current practice based on small case series or unpublished experience. Medical treatment is likely beneficial for male teenagers seeking attention for pubertal delay to prevent psychosocial distress. While watchful waiting is appropriate for boys aged 12-14 with suspected constitutional delay of growth and puberty, hormone replacement should not be delayed beyond the age of 14. Hormone replacement should be proposed by the age of 12 when hypogonadism is diagnosed. Testosterone replacement is the standard treatment, but aromatase inhibitors have emerged as an interesting alternative. Gonadotrophin therapy appears more physiological for patients with central hypogonadism, but its efficacy and timing still need further research.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Review Biochemistry & Molecular Biology

Anti-Mullerian Hormone and Polycystic Ovary Syndrome in Women and Its Male Equivalent

Nathalie di Clemente, Chrystele Racine, Rodolfo A. Rey

Summary: This article reviews the main findings on anti-Mullerian hormone (AMH) and its involvement in the pathogenesis of polycystic ovary syndrome (PCOS) and its male equivalent. AMH has important roles in ovarian reserve, follicular development, and the differentiation of the genital tract. It is also used to assess Sertoli cell function in children and has potential implications for male fertility.

BIOMEDICINES (2022)

Editorial Material Endocrinology & Metabolism

Taming Idiopathic Central Precocious Puberty: High Frequency of Imprinting Disorders in Familial Forms

Lourdes Correa Brito, Rodolfo A. Rey

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Article Health Care Sciences & Services

Identification of a Novel Variant in Myelin Regulatory Growth Factor by Next-Generation Sequencing Led to the Detection of a Clinically Inapparent Congenital Heart Defect in a Patient with a 46,XY Disorder of Sex Development

Lourdes Correa Brito, Romina P. Grinspon, Jimena Lopez Dacal, Paula Scaglia, Maria Esnaola Azcoiti, Agustin Izquierdo, Maria Gabriela Ropelato, Rodolfo A. Rey

Summary: This study reported a case of a patient with 46,XY disorders of sex development (DSDs) in whom a novel variant in MYRF gene was identified, leading to the detection of a clinically inapparent congenital heart defect.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Meeting Abstract Endocrinology & Metabolism

EFFECT OF CHEMOTHERAPY ON ENDOCRINE TESTICULAR FUNCTION DURING CHILDHOOD AND PUBERTY IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA OR NON-HODGKIN LYMPHOMA: A PROSPECTIVE, LONGITUDINAL STUDY

Luciana Brenzoni, Silvina Prada, Maria Arozarena de Gamboa, Maria Gabriela Ropelato, Maria Gabriela Ballerini, Maria Eugenia Rodriguez, Marcela E. Gutierrez, Patricia Bedecarras, Luis Aversa, Rodolfo A. Rey, Romina P. Grinspon, Romina Paula Grinspon

HORMONE RESEARCH IN PAEDIATRICS (2021)

No Data Available